GlassScriptPhysician profile
Mohammad Kamsheh
NPI 1083611917
$11,582.16
in general payments reported to CMS, 2019-2025
62 companies · $3,534 in 2025
The $3,534 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $794 · 2021: $212 · 2022: $850 · 2023: $1,360 · 2024: $2,653 · 2025: $3,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,137 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,136.65 |
| Education | $410.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,222.03 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $880.23 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $761.57 | 2019-2025 | |
| Lilly USA, LLC | $623.41 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Amneal Pharmaceuticals LLC | $608.70 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Emd Serono, INC. | $529.67 | 2019-2025 | Mavenclad |
| Harmony Biosciences LLC | $497.24 | 2023-2025 | Wakix |
| Biogen, INC. | $472.83 | 2019-2024 | Vumerity, Avonex, Tysabri |
| Amgen INC. | $411.40 | 2019-2025 | Uplizna |
| Ucb, INC. | $373.81 | 2019-2025 | Rystiggo, Briviact |
| Pfizer INC. | $353.26 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $312.22 | 2022 | |
| Neurocrine Biosciences, INC. | $258.60 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $247.70 | 2019-2025 | Vyepti, Rexulti |
| Mallinckrodt Hospital Products INC. | $212.52 | 2020-2025 | Acthar |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kamsheh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.